Aqueous injectable formulations incorporating the liquid botanical API (Sanhua Danggui Perfusion Solution Veterinary Grade) are compounded in a nitrogen-sparged stainless-steel 316L vessel at 20–25°C, with the API added at 2.0–4.5% w/v to Water for Injection that has been cooled below 8°C to reduce oxidative degradation of the Z-ligustilide fraction during bulk hold. Above 4.5% w/v, the polysaccharide component tends to form filter-fouling aggregates if the pH drifts below 4.0; buffering to 5.0–5.8 with anhydrous citric acid and sodium hydroxide before filtration is therefore the standard control point. The finished bulk is filtered through a 0.45 µm polypropylene clarification cartridge followed by a 0.22 µm PVDF sterilizing membrane; membrane flux decline to less than 10 L/m²/h indicates a rejected batch or a required prefiltration adjustment. Terminal sterilization is limited to 121°C for 15 min at an F₀ of 8–12, because published stability data on ligustilide-bearing botanical extracts show measurable degradation under more aggressive autoclave cycles. Sterility is verified according to USP <71> and Ph. Eur. 2.6.1; bacterial endotoxin limits follow USP <85> and Ph. Eur. 2.6.14 for parenteral preparations intended for large-animal intravenous or intramuscular administration. Residual solvent compliance is assessed under VICH GL18 if the API contains extraction solvents above defined threshold limits.

On filling lines, rotary piston pumps with ceramic or stainless-steel 316L wetted parts are used because the extract accelerates rusting in plain carbon steel and can complex with copper and iron ions; stainless-steel 316L passivation per ASTM A967 is recommended. Multi-dose rubber-stoppered vials of 100 mL and 250 mL receive nitrogen overlay during filling, and the closure system is selected from bromobutyl elastomer tested for compatibility across the intended shelf life. Single-dose glass ampoules of 50 mL are also produced. If a multi-dose presentation is filled without preservative, the recovery period after first puncture must be validated, and antimicrobial preservative efficacy testing according to USP <51> or Ph. Eur. 5.1.3 is required when the formulation contains a preservative system.

What Solvent Partitioning Parameters Allow a Stable Oral Drench at 1.0% w/v?

In oral drench lines for neonatal calves and lambs, the liquid API is diluted at 0.8–1.5% w/v in a co-solvent system of propylene glycol and purified water at a 60:40 ratio, with the pH buffered to 6.0–6.8 using phosphate buffer. This ratio maintains the weakly polar marker fraction in solution at 2–8°C; batch records from farm-pack drench operations indicate that precipitation occurs when propylene glycol content drops below 40% or when the final product is stored below -5°C. Production-scale compounding uses a closed recirculating mixing vessel at 150–300 rpm, with a vacuum deaeration step at -0.8 bar to control foam generated by the saponin-like fraction. Filling into high-density polyethylene bottles of 500 mL, 1 L, and 5 L is performed at 10–20°C; line back-pressure fluctuations greater than 0.5 bar indicate viscosity drift outside the specified 5–12 cP range.

Microbiological acceptance for oral solutions is based on Ph. Eur. 5.1.4 or USP <1111> for non-sterile preparations; total aerobic microbial count is controlled at not more than 10² CFU/mL and total combined yeasts and molds at not more than 10¹ CFU/mL. Residual solvent compliance is tested under VICH GL18 if ethanol or ethyl acetate is used as the extraction solvent. The drench is not autoclaved because heat above 80°C accelerates formation of degradation products detectable as total peak purity loss by HPLC. Terminal packs are sealed with induction-foil closures to minimize oxygen ingress. The main incompatibility is with polyvalent metal salts, especially ferric chloride and alum, which cause immediate darkening and sediment; all wetted equipment is therefore limited to high-density polyethylene, polypropylene, or stainless-steel 316L.

For drinking-water soluble granule production, the liquid botanical API is converted into a sprayable feed by dilution 1:1 with purified water and applied by top-spray fluid-bed granulation onto a water-soluble carrier blend of lactose monohydrate, maltodextrin, and povidone K30 at a carrier-to-liquid API ratio of 100:8 to 100:12. The diluted liquid is held below 15 cP before atomization; at higher viscosity the two-fluid nozzle produces irregular agglomerates and the bed collapses. Inlet air is held at 45–55°C, product temperature at 30–35°C, and spray rate at 30–50 g/min per kg of bed mass. After spraying, the granulate is dried to a loss on drying ≤3.0% and screened through a 710 µm sieve; fines below 150 µm are recycled only if the recycled fraction is ≤20% of the next batch to avoid dusting and segregation. Granules are packed in 100 g, 500 g, and 1 kg aluminium-foil pouches; the selected film laminate provides a moisture vapour transmission rate below 0.5 g/m²/day.

Compliance for drinking-water additive powders is assessed against Ph. Eur. 5.1.4 or USP <1111>; reconstitution time is tested in tap water at 10–15°C and must not exceed 120 s without residue on a 250 µm screen. Equipment contact surfaces are stainless-steel 316L and silicone seals; long hold times in carbon steel transfer lines are not accepted because the extract fraction can initiate surface oxidation. The finished granule is administered after dilution in stock solutions of 1–5% w/v and then proportionally metered into drinking water lines; published data for specific species dosage adjustment remains limited and must be verified by the marketing authorization holder. Terminal formats include water-soluble granule pouches and bulk pails of 5 kg for farm stock medication.

When Direct Compression Fails Due to Hygroscopic Capture Moisture Above 12%

Veterinary tablets and capsules using the liquid API are produced by first converting the extract into a free-flowing adsorbate. A common adsorption ratio is 1.0 kg of liquid API onto 0.8–1.2 kg of microcrystalline cellulose and 0.3–0.5 kg of colloidal silicon dioxide, conditioned at 25–30°C for 6–8 h in a paddle mixer at 50–80 rpm. Direct compression is attempted only when the equilibrium moisture content of the adsorbate is ≤12% w/w; above this threshold, tablets exhibit picking and sticking on 10 mm flat-faced bevelled punches. The adsorption step is followed by blending with croscarmellose sodium 2.0–5.0% w/w, microcrystalline cellulose to final weight, and magnesium stearate 0.5–1.0% w/w; the blend is compressed on a 16-station rotary tablet press at 8–15 kN. Tablet hardness is maintained at 50–80 N, friability is controlled below 1.0% according to USP <1216>, and disintegration is tested according to USP <701> with a 15-min limit in water at 37°C. Dissolution testing follows USP <711> using 900 mL of pH 6.8 phosphate buffer and paddle speed 50 rpm; release criteria are established by the marketing authorization holder.

Capsule products are filled with the same granulate into size 2 or 3 hard gelatin or hypromellose capsules to deliver 20–40 mg of the dried API adsorbate per unit; uniformity of dosage units is verified by USP <905>. The manufacturing process is subject to 21 CFR 210/211 for veterinary finished pharmaceuticals, and cleaning validation limits are set according to a risk-based matrix. Tablet and capsule presentations are intended for companion-animal dispensing in blister packs of 10 or 30 units and for calf bolus formats from 1.0 g to 3.0 g. The most frequent process deviation on direct compression lines is segregation of the low-density adsorbate during hopper discharge; this is corrected by matching hopper level to a mass-flow design and keeping the blend bulk density within 0.45–0.65 g/mL.

Feed Premix Adsorbate Ratios and Pellet Die Friction Constraints

Feed integration starts with preparation of a 20% w/w liquid API adsorbate on feed-grade precipitated silica or calcium carbonate at a ratio of 1.0 kg liquid API to 4.0 kg carrier. The short-mix paddle blender runs at 80–120 rpm for 10–12 min; incomplete adsorption is detected by a torque rheometer plateau or by visual agglomeration. The resulting premix is added into the main ribbon mixer at 0.5–2.5 kg of 20% premix per tonne of finished feed. Mixing uniformity is validated by ISO 6497:2005 sampling procedures; the target coefficient of variation across 10 sampled points is ≤5%. Compliance is framed under Regulation (EC) No 1831/2003 for zootechnical or sensory feed additive claims and Regulation (EC) No 183/2005 for feed hygiene; if the product is positioned as a veterinary medicated premix, Regulation (EU) 2019/6 veterinary medicinal product requirements apply. Residual solvent testing follows VICH GL18; heavy metal limits are aligned with Ph. Eur. 2.4.8 or the relevant regional feed contaminant schedule.

Pelleting through a 6 mm die with a length-to-diameter ratio of 1:8 is run at conditioning temperatures of 65–75°C. Conditioning above 75°C for more than 30 s has been associated with reduced recovery of the volatile phthalide fraction in test pellets; therefore process validation includes pre- and post-pellet HPLC marker recovery. When the computed loss exceeds 10%, the preferred control measure is post-pelleting liquid application through a vacuum coater or spray nozzle rather than increasing premix input. Terminal formats include 25 kg multi-wall paper bags with a polyethylene inner liner for the 20% premix, complete mash feed, and 3–6 mm pelleted feed. Bagged premix is stored below 30°C and 65% RH; above these conditions the adsorbed liquid API softens and may cause the premix to bridge in the hopper.

Aseptic Compounding of an Intrauterine Perfusion Concentrate Without Terminal Heat

This is the highest-risk liquid processing route because the product is used for bovine uterine infusion and therefore operates at the interface between non-sterile and aseptic production. The liquid API is compounded at 10–20% w/v into a vehicle of purified water, glycerin, and a pH-modifying buffer to a final pH of 5.5–6.5. The bulk is mixed with a magnetic or bottom-mounted agitator at 60–120 rpm; high-shear rotor-stator mixing is avoided because it generates foam and introduces air that accelerates oxidative degradation. The solution is clarified through a 0.45 µm filter and filled into 100 mL or 200 mL high-density polyethylene bottles or multilayer polyolefin fluid bags. Terminal steam sterilization is not applied because the thermal exposure degrades the active marker fraction and shifts the pH downward; aseptic filling is therefore used, with bioburden before sterile filtration controlled at ≤10 CFU/100 mL after 48 h of bulk hold.

Microbiological quality is evaluated under Ph. Eur. 5.1.4 for non-sterile aqueous preparations unless the label claims sterility, in which case USP <71> and Ph. Eur. 2.6.1 apply. Bacterial endotoxin is tested by USP <85> or Ph. Eur. 2.6.14 when the route of administration requires a pyrogen-controlled claim. The limit for particulate matter is monitored by liquid particle counting; containers are rejected if counts at ≥10 µm exceed 25 particles/mL. The product is diluted at the farm level with 0.9% sterile saline or warmed sterile water at a ratio of 1:5 to 1:20 before infusion. The principal incompatibility is with benzalkonium chloride above 0.01% and with povidone-iodine residues in the infusion line; both cause flocculation and loss of clarity. Published production-scale data for this specific extract in intrauterine perfusion is limited; therefore filter compatibility and hold-time studies must be carried out on the actual batch formulation.